Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Gliclazide
18 general benefit · 1 not a benefit
Apo-Gliclazide MR · DIN 02297795 · 30 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Gliclazide MR · DIN 02297795
Manufacturer: Apotex Inc.; listing date 2008-08-28
Health Canada: Marketed since 2014-12-12 · brand APO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02297795)
Source record
DIN 02297795: Apo-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id APX
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297795
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78313
Interchangeable products
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended March 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297795
Shortage record checked October 6, 2026
Diamicron MR · DIN 02242987 · 30 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Diamicron MR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Diamicron MR · DIN 02242987
Manufacturer: Servier Canada Inc.; listing date 2007-04-02
Health Canada: Marketed since 2001-04-04 · brand DIAMICRON MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Servier canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242987)
Source record
DIN 02242987: Diamicron MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SEV
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.1660; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242987
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66827
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended December 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242987
Shortage record checked October 6, 2026
Jamp Gliclazide MR · DIN 02429764 · 30 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Gliclazide MR · DIN 02429764
Manufacturer: Jamp Pharma Corporation; listing date 2015-05-28
Health Canada: Marketed since 2024-10-04 · brand JAMP GLICLAZIDE-MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02429764)
Source record
DIN 02429764: Jamp Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id JPC
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02429764
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91420
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended November 10, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429764
Shortage record checked October 6, 2026
Mint-Gliclazide MR · DIN 02423286 · 30 mg · extended release tablet
General benefitMarketed · checked November 16, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Gliclazide MR · DIN 02423286
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-06-02 · brand MINT-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02423286)
Source record
DIN 02423286: Mint-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id MIN
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02423286
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90799
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended November 5, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423286
Shortage record checked October 6, 2026
Mylan-Gliclazide MR · DIN 02438658 · 30 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mylan-Gliclazide MR · DIN 02438658
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-10-30
Health Canada: Marketed since 2015-08-07 · brand MYLAN-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMylan-Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02438658)
Source record
DIN 02438658: Mylan-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id MYL
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02438658
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92302
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended August 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02438658
Shortage record checked October 6, 2026
Taro-Gliclazide MR · DIN 02463571 · 30 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Gliclazide MR · DIN 02463571
Manufacturer: Sun Pharma; listing date 2020-08-28
Health Canada: Marketed since 2021-02-22 · brand TARO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02463571)
Source record
DIN 02463571: Taro-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SPC
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02463571
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95168
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Shortage status: resolved shortage (ended November 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02463571
Shortage record checked October 6, 2026
Apo-Gliclazide MR · DIN 02407124 · 60 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Gliclazide MR · DIN 02407124
Manufacturer: Apotex Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-04-14 · brand APO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Gliclazide MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02407124)
Source record
DIN 02407124: Apo-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id APX
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02407124
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89182
Interchangeable products
Diamicron MR · DIN 02356422 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02407124
Shortage record checked October 6, 2026
Diamicron MR · DIN 02356422 · 60 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Diamicron MR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Diamicron MR · DIN 02356422
Manufacturer: Servier Canada Inc.; listing date 2011-08-04
Health Canada: Marketed since 2010-12-09 · brand DIAMICRON MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Servier canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02356422)
Source record
DIN 02356422: Diamicron MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SEV
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.2990; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02356422
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84157
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended February 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356422
Shortage record checked October 6, 2026
Jamp Gliclazide-MR · DIN 02429772 · 60 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Gliclazide-MR · DIN 02429772
Manufacturer: Jamp Pharma Corporation; listing date 2024-12-30
Health Canada: Marketed since 2024-10-04 · brand JAMP GLICLAZIDE-MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Gliclazide-MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02429772)
Source record
DIN 02429772: Jamp Gliclazide-MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id JPC
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02429772
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91421
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Diamicron MR · DIN 02356422 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended January 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429772
Shortage record checked October 6, 2026
Mint-Gliclazide MR · DIN 02423294 · 60 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Gliclazide MR · DIN 02423294
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-04-27
Health Canada: Marketed since 2025-04-16 · brand MINT-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Gliclazide MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02423294)
Source record
DIN 02423294: Mint-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id MIN
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02423294
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90800
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Diamicron MR · DIN 02356422 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended April 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423294
Shortage record checked October 6, 2026
Taro-Gliclazide MR · DIN 02439328 · 60 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Gliclazide MR · DIN 02439328
Manufacturer: Sun Pharma; listing date 2017-09-28
Health Canada: Marketed since 2021-02-22 · brand TARO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Gliclazide MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02439328)
Source record
DIN 02439328: Taro-Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SPC
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02439328
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92369
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Diamicron MR · DIN 02356422 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Shortage status: resolved shortage (ended May 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439328
Shortage record checked October 6, 2026
Apo-Gliclazide · DIN 02245247 · 80 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Gliclazide · DIN 02245247
Manufacturer: Apotex Inc.; listing date 2007-06-06
Health Canada: Marketed since 2002-07-02 · brand APO-GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Gliclazide: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245247)
Source record
DIN 02245247: Apo-Gliclazide
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id APX
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245247
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69269
Interchangeable products
Diamicron · DIN 00765996 · not recorded
Gliclazide · DIN 02287072 · $0.0931
Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: resolved shortage (ended October 9, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245247
Shortage record checked October 6, 2026
Gliclazide · DIN 02287072 · 80 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Gliclazide · DIN 02287072
Manufacturer: Sanis Health Inc.; listing date 2011-09-15
Health Canada: Marketed since 2014-06-10 · brand GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGliclazide: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02287072)
Source record
DIN 02287072: Gliclazide
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id SAI
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02287072
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77250
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931
Diamicron · DIN 00765996 · not recorded
Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02287072
Shortage record checked October 6, 2026
Teva-Gliclazide · DIN 02238103 · 80 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Gliclazide · DIN 02238103
Manufacturer: Teva Canada Limited; listing date 2007-06-06
Health Canada: Marketed since 2014-02-11 · brand TEVA-GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Gliclazide: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238103)
Source record
DIN 02238103: Teva-Gliclazide
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id TEV
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238103
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61497
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931
Diamicron · DIN 00765996 · not recorded
Gliclazide · DIN 02287072 · $0.0931
Shortage status: resolved shortage (ended February 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238103
Shortage record checked October 6, 2026
Gliclazide MR · DIN 02524856 · 30 mg · extended release tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.Discontinued July 23, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gliclazide MR · DIN 02524856
Manufacturer: Sanis Health Inc.; listing date 2022-09-29
Health Canada: Cancelled post market since 2026-07-23 · brand GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524856)
Source record
DIN 02524856: Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SAI
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524856
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101386
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: active shortage (reported November 1, 2024, last updated January 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524856
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 23, 2026 — choose a marketed DIN from the same-category list.
Sandoz Gliclazide MR · DIN 02461323 · 30 mg · extended release tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Gliclazide MR · DIN 02461323
Manufacturer: Sandoz Canada Inc.; listing date 2020-07-31
Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Gliclazide MR: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461323)
Source record
DIN 02461323: Sandoz Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SDZ
Source form: SR Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461323
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94883
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931
Diamicron MR · DIN 02242987 · $0.0931
Gliclazide MR · DIN 02524856 · $0.0931
Jamp Gliclazide MR · DIN 02429764 · $0.0931
Mint-Gliclazide MR · DIN 02423286 · $0.0931
Mylan-Gliclazide MR · DIN 02438658 · $0.0931
Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: discontinued (December 6, 2024, reported by SANDOZ CANADA INCORPORATED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461323
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 31, 2026 — choose a marketed DIN from the same-category list.
Gliclazide MR · DIN 02524864 · 60 mg · extended release tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.Discontinued July 23, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gliclazide MR · DIN 02524864
Manufacturer: Sanis Health Inc.; listing date 2022-09-29
Health Canada: Cancelled post market since 2026-07-23 · brand GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGliclazide MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524864)
Source record
DIN 02524864: Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SAI
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524864
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101387
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Diamicron MR · DIN 02356422 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: active shortage (reported March 26, 2025, last updated January 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524864
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 23, 2026 — choose a marketed DIN from the same-category list.
Sandoz Gliclazide MR · DIN 02461331 · 60 mg · extended release tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Gliclazide MR · DIN 02461331
Manufacturer: Sandoz Canada Inc.; listing date 2017-08-30
Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Gliclazide MR: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461331)
Source record
DIN 02461331: Sandoz Gliclazide MR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SDZ
Source form: ER Tab; strength: 60mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.0632; ministry $0.0632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461331
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94884
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632
Diamicron MR · DIN 02356422 · $0.0632
Gliclazide MR · DIN 02524864 · $0.0632
Jamp Gliclazide-MR · DIN 02429772 · $0.0632
Mint-Gliclazide MR · DIN 02423294 · $0.0632
Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: discontinued (December 6, 2024, reported by SANDOZ CANADA INCORPORATED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461331
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 31, 2026 — choose a marketed DIN from the same-category list.
Diamicron · DIN 00765996 · 80 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.Discontinued October 18, 2022 · checked November 16, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Diamicron · DIN 00765996
Manufacturer: Servier Canada Inc.; listing date 2007-04-02
Health Canada: Cancelled post market since 2022-10-18 · brand DIAMICRON · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Pharmed · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordDiamicron: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00765996)
Source record
DIN 00765996: Diamicron
Raw flags: chronicUseMed=Y, insOH=Y, notABenefit=Y, sec3=Y
Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id SEV
Source form: Tab; strength: 80mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00765996
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10918
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931
Gliclazide · DIN 02287072 · $0.0931
Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: discontinued (September 30, 2022, reported by SERVIER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00765996
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 18, 2022 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (A10B, A10BB): coverage varies; not interchangeable
- Glyburide (Apo-Glyburide): general benefit, not a benefit
- Glimepiride (Amaryl): not a benefit
- Canagliflozin (Invokana): general benefit
- Dapagliflozin (Forxiga): general benefit
- Dapagliflozin + metformin (Xigduo): general benefit
- Empagliflozin (Jardiance): general benefit
12 more in the class list below
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered
Matched class: 68:20:02 Oral Anti-Diabetic Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN
Some products covered without a code (check the product listing): GLYBURIDE, METFORMIN HCL
68:20:02 Oral Anti-Diabetic Agents
· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 4mg · Tab
· 8 products · General benefit · strengths: 100mg, 300mg · Tab
· 22 products · General benefit · strengths: 5mg, 10mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab
· 2 products · General benefit · strengths: 10mg, 25mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab
· 1 products · General benefit · strengths: 5mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab
· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02
and 6 more
Full class listing
Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Availability
Gliclazide MR · DIN 02524856
Shortage status: active shortage (reported 2024-11-01, last updated 2026-01-06); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524856
Check this DIN againSandoz Gliclazide MR · DIN 02461323
Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461323
Check this DIN againGliclazide MR · DIN 02524864
Shortage status: active shortage (reported 2025-03-26, last updated 2026-01-06); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524864
Check this DIN againSandoz Gliclazide MR · DIN 02461331
Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461331
Check this DIN againDiamicron · DIN 00765996
Shortage status: discontinued (2022-09-30, reported by SERVIER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00765996
Check this DIN again